To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

Inclusion Criteria: * Have a body Mass Index (BMI) between 18 to 32 kg/m2 (both inclusive). * Medical history without any major pathology. * A sustained supine systolic blood pressure \<150 mm Hg or \>90 mm Hg or a supine diastolic blood pressure \<95 mm Hg or \>50 mm Hg at Screening or Check-in (Day -1). Blood pressure may be retested once in the supine position. * Glomerular filtration rate (GFR) \> 80 mL/min, estimated by the Cockcroft-Gault equation. Exclusion Criteria: * Use of cefepime and/or tazobactam within 60 days prior to study drug administration. * History or evidence of clinically relevant pathology which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.